Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BMRN vs SYRE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BMRN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

BMRN Overall Winner 6-Pillar Tally: BMRN 6 – 0 SYRE Matrix Metrics: BMRN 8 – 2 SYRE

As of Nov 16, 2026, BioMarin Pharmaceuticals Inc (BMRN) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRN carries a Unified Composite Score of 52.6/100 (HOLD) at $58.32 (9.1x Forward P/E, 16.3% operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BMRN vs SYRE
BMRN NASDAQ Head-to-Head Winner
BioMarin Pharmaceuticals Inc
Pharmaceutical Preparations
$58.32
+1.9% 1D
Market Cap $11.0B
TTM Revenue $3.66B
Forward P/E 9.1x
Beta / 30D Vol 0.28β · 31% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 57.0 Fund 61.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.0 · SMA20: $56.73 · SMA50: $58.69
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.5 · SMA20: $98.78 · SMA50: $91.70

6-Pillar Scorecard Institutional Category Breakdown (BMRN 6 – 0 SYRE)

Columns: Metric · BMRN · SYRE
1. Valuation Multiples BMRN
Forward P/E 9.1x N/M
Trailing P/E 8.8x N/M
PEG Ratio 0.34x N/M
EV / Revenue 3.9x N/M
2. Growth & Scale BMRN
Revenue Growth (YoY) +32.0% +0.0%
Earnings Growth (YoY) -81.3% -99.7%
TTM Revenue (USD) $3.66B N/A
Market Cap $11.0B $9.8B
3. Profitability & Quality BMRN
Gross Margin 53.2% N/A
Operating Margin 16.3% 0.0%
Net Profit Margin -0.5% 0.0%
Return on Equity (ROE) -0.3% -35.0%
4. Balance Sheet & Cash Flow BMRN
Cash Generation (TTM) $554M N/A
Cash Flow Margin 15.2% N/A
Net Cash / Leverage $3.45B Net Debt (0.67x D/E) $10.06 Book/Sh · -35.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BMRN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 37.4% (17th %ile) 87.9% (10th %ile)
Put/Call OI Skew 0.06x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat BMRN
OpEx & R&D Intensity 36.9% of Rev ($1.35B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BMRN (8) vs SYRE (2)
Institutional Metric BMRN SYRE Criterion Row Edge
Market Capitalization
Scale
$11.0B $9.8B Larger Scale BMRN
Trailing P/E Ratio
Valuation
8.8x N/M Lower Multiple BMRN
Forward P/E Ratio
Valuation
9.1x N/M Lower Multiple BMRN
Revenue Growth (YoY)
Growth
+32.0% +0.0% Higher Growth BMRN
Operating Margin (TTM)
Profitability
16.3% 0.0% Higher Margin BMRN
Net Profit Margin
Profitability
-0.5% 0.0% Higher Margin SYRE
Return on Equity (ROE)
Capital Efficiency
-0.3% -35.0% Higher ROE BMRN
52-Week Range Position
Momentum
42% ($49–$71) 88% ($22–$111) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
0.28β · 31% Vol 1.75β · 59% Vol Lower Realized Risk BMRN
Unified Institutional Score
Composite Signal
52.6 / 100 (HOLD) 44.4 / 100 (HOLD) Higher Composite BMRN
Trailing 12M Revenue (USD)
Operating Scale
$3.66B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.34x PEG · 3.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$554M ($3.45B Net Debt (0.67x D/E)) N/A ($10.06 Book/Sh · -35.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +18.45 pp
BMRN: +6.66% · SYRE: +25.11%
3M Horizon SYRE +5.65 pp
BMRN: -12.94% · SYRE: -7.29%
6M Horizon SYRE +25.23 pp
BMRN: +17.41% · SYRE: +42.64%
1Y Horizon SYRE +334.18 pp
BMRN: +7.56% · SYRE: +341.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BMRN vs SYRE. Trailing 12-month operating profitability (BMRN 16.3% vs SYRE 0.0%) and valuation multiples (BMRN 9.1x vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BMRN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.66B
Gross Margin53.2%
Op. Margin16.3%
ROE / Fwd P/E-0.3% · 9.1x
SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BMRN CONSOLIDATION
67d in phase · OBV DISTRIBUTION
Current IV 37.4%
IV Percentile 17th %ile
Put/Call OI Skew 0.06x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact BMRN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BMRN Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $11.0B market capitalization and 16.3% operating margin.
OpEx & R&D Reinvestment 36.9% of Rev ($1.35B)
90D Engineering Disclosures 0 Published
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BMRN vs SYRE Key Questions & Quantitative Answers

As of Nov 16, 2026, BioMarin Pharmaceuticals Inc (BMRN) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRN carries a Unified Composite Score of 52.6/100 (HOLD) at $58.32 (9.1x Forward P/E, 16.3% operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin). Technically, BMRN sits in a Neutral phase (RSI 54.0, CONSOLIDATION options structure) and SYRE sits in a Neutral phase (RSI 53.5, UNCLASSIFIED options structure).

BMRN leads the Growth & Scale pillar: BMRN posts +32.0% YoY revenue growth and -81.3% YoY earnings growth on $3.66B TTM revenue (53.2% gross margin, 16.3% operating margin), compared with SYRE at +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, BMRN generates $3.66B in USD-normalized revenue versus N/A for SYRE. In operating R&D and SG&A reinvestment, BMRN deploys 36.9% of Rev ($1.35B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SYRE.

BMRN screens cheaper on headline valuation multiples. BMRN trades at 9.1x Forward P/E, 8.8x Trailing P/E, 0.34x PEG, and 3.9x EV/Revenue (15.2% FCF margin), whereas SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRN (-0.3% ROE) versus SYRE (-35.0% ROE) capital efficiency.

In options market volatility and institutional positioning, BMRN carries 37.4% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.28β · 31% Vol realized risk). By comparison, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.